AstraZeneca, Breast Cancer
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with unresectable or metastatic hormone receptor (HR)-positive,
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
AstraZeneca PLC ADR closed 22.49% short of its 52-week high of $87.68, which the company reached on August 30th.
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
AstraZeneca (AZN) has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
AstraZeneca PLC AZN shares rallied 2.39% to £110.52 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.33% to 8,548.29.
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £155.58. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback